Core Viewpoint - Olema Pharmaceuticals, Inc. (OLMA) shows significant upside potential with a mean price target of $24.71, indicating a 386.4% increase from the current price of $5.08 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $18 to a high of $30, with a standard deviation of $4.64, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 254.3%, while the highest suggests a 490.6% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about OLMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.4%, with five estimates moving higher and no negative revisions [12] Zacks Rank - OLMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]

Financial Data and Key Metrics Changes - The company is currently conducting a phase three pivotal trial focused on hormone receptor positive, HER2 negative breast cancer, with the lead asset being palisestrant [2][3] - The ongoing phase three trial is a monotherapy trial in the second and third line setting, with top-line results expected next year [3] - The company plans to initiate a first-line trial in the second half of the year, which will include ribociclib [3][4] Business Line Data and Key Metrics Changes - The company has two clinical stage assets: palisestrant in phase three and OP3136, a CAT6 inhibitor, in phase one dose escalation [4] - The phase two data for palisestrant showed a progression-free survival (PFS) of 7.3 months in the ESR1 mutant population, which is significantly better than the control arm [13] - The combination of ribociclib and palisestrant is expected to show favorable results compared to other combinations, with a median PFS of 15 months reported [20][21] Market Data and Key Metrics Changes - The company is competing in a rapidly evolving market for oral SERDs, with recent trials showing benefits primarily in ESR1 mutant patients [6][7] - The company aims to differentiate palisestrant by demonstrating its efficacy in both mutant and wild-type populations [13][18] Company Strategy and Development Direction - The company is focused on advancing its clinical trials and establishing palisestrant as a competitive treatment option in the breast cancer market [2][3] - The strategy includes a combination approach with ribociclib and palisestrant, which is expected to enhance treatment outcomes [20][21] - The company is also exploring the potential of OP3136 in various cancer types, including castration-resistant prostate cancer and non-small cell lung cancer [42][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the efficacy of palisestrant in the first-line setting, particularly for treatment-naive patients [25] - The company anticipates that the upcoming data updates will provide further insights into the performance of its assets and their potential market impact [33][34] Other Important Information - The company has a clinical collaboration with Novartis for the supply of ribociclib, which is a key component of its trials [30] - The company is preparing for potential data updates and has several catalysts expected later this year [34][46] Q&A Session Summary Question: How does palisestrant differentiate from other oral SERDs? - Management highlighted that palisestrant is a complete estrogen receptor antagonist, unlike others that are partial agonists, which may limit their efficacy in certain populations [6][7] Question: What are the expectations for the OPERA one trial design? - The trial is designed to test both mutant and wild-type populations separately, allowing for a more targeted statistical analysis [18] Question: How does the combination of ribociclib and palisestrant compare to other treatments? - The combination is expected to show significantly better results than existing treatments, with a median PFS of 15 months compared to 5 months in previous studies [20][21]

Financial Performance - Olema reported net losses of $30.4 million for Q1 2025, compared to $31.0 million for Q1 2024, with an accumulated deficit of $465.5 million as of March 31, 2025[135]. - The net loss for Q1 2025 was $30.4 million, compared to a net loss of $31.0 million in Q1 2024, reflecting an improvement of $0.6 million[158]. - General and administrative expenses for Q1 2025 were $4.2 million, a decrease of $0.2 million from $4.5 million in Q1 2024, mainly due to a reduction in non-cash stock-based compensation[156]. - Research and development expenses for Q1 2025 were $30.6 million, an increase of $0.7 million from $29.9 million in Q1 2024, primarily due to increased spending on clinical operations and personnel-related costs[155]. - The company has not generated any revenue from product sales since inception and expects to incur significant operating losses for the foreseeable future[165]. - The company has not generated any revenue from product sales to date and does not expect meaningful revenue until regulatory approval and commercialization of product candidates occur[168]. Research and Development - The ongoing Phase 3 clinical trial of palazestrant (OP-1250) is expected to yield top-line results in 2026[128]. - The median progression-free survival (mPFS) for patients treated with palazestrant and ribociclib was reported at 13.8 months, with 40 out of 56 patients having prior treatment with a CDK4/6 inhibitor[131]. - Olema's second product candidate, OP-3136, has entered Phase 1 clinical trials after receiving IND clearance from the FDA in late 2024[132]. - Olema plans to continue its research and development efforts for palazestrant and OP-3136, as well as seek regulatory approvals for successful candidates[139]. - The company anticipates increased research and development and general administrative costs as it conducts additional studies and trials for its product candidates[165]. Funding and Capital Requirements - The company expects to require substantial additional funding to support ongoing operations and product development[138]. - The company entered into a loan agreement increasing the credit facility from $50.0 million to $100.0 million, with $25.0 million currently available[160]. - The company raised approximately $250.0 million through a private placement of common stock in November 2024, netting approximately $237.0 million after expenses[161]. - Future capital requirements will depend on various factors, including the pace of development efforts and the ability to establish collaborations on favorable terms[174]. - The company may need to rely on additional financing through equity offerings, debt financings, collaborations, and licensing arrangements[172]. Cash Flow and Liquidity - As of March 31, 2025, the company had $392.7 million in cash, cash equivalents, and marketable securities, with an accumulated deficit of $465.5 million[159]. - As of March 31, 2025, the company expects its cash, cash equivalents, and marketable securities will fund its operating plan for at least the next 12 months[169]. - Net cash used in operating activities for the three months ended March 31, 2025, was $43.979 million, compared to $23.496 million for the same period in 2024[175]. - Net cash used in investing activities for the three months ended March 31, 2025, was $45.083 million, primarily due to purchases of marketable securities[178]. - Net cash provided by financing activities for the three months ended March 31, 2025, was $0.222 million, mainly from the exercise of stock options[179]. Operational Outlook - The company anticipates significant and increasing operating losses as it advances its product candidates and operates as a public entity[137]. - Olema relies on third parties for manufacturing and does not plan to establish its own manufacturing facilities[134]. - The company anticipates significant commercialization expenses if marketing approval for product candidates is obtained[171]. - The company has no outstanding debt as of March 31, 2025, and currently has no financing commitments expected to affect liquidity over the next five years[167]. - There were no material changes to critical accounting policies and market risk disclosures during the three months ended March 31, 2025[181][182].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 780 Brannan Street San Francisco, California 94103 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Cod ...

Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 studyPivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress poster to be highlighted at ASCO Annual MeetingPreclinical data for OP-3136 presented at AACR demonstrating anti-tumor ...

Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancerPatient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor typesData to be presented at 2025 AACR Annual Meeting SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical ...

Core Viewpoint - Olema Pharmaceuticals, Inc. (OLMA) has shown a significant price increase of 21% over the past four weeks, with a mean price target of $26.71 indicating a potential upside of 433.1% from the current price of $5.01 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from a low of $20 to a high of $30, with a standard deviation of $3.45, suggesting a high degree of agreement among analysts [2] - The lowest estimate indicates a potential increase of 299.2%, while the most optimistic estimate suggests a 498.8% upside [2] - A low standard deviation indicates that analysts have a high degree of consensus regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about OLMA's earnings prospects, as indicated by a strong agreement in revising EPS estimates higher, which correlates with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 5.5% over the past month, with two estimates going higher and no negative revisions [12] - OLMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

A downtrend has been apparent in Olema Pharmaceuticals, Inc. (OLMA) lately with too much selling pressure. The stock has declined 30.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical ind ...

Group 1 - Olema Pharmaceuticals, Inc. is focused on developing treatment options for breast cancer, particularly the most common molecular subtype [1] - The company is currently in late-stage clinical trials, indicating significant progress in its drug development pipeline [1] Group 2 - The article emphasizes the importance of understanding the science behind biotech investments to avoid potential pitfalls [1]

Core Insights - Olema Pharmaceuticals is set to present preclinical data on OP-3136, a selective KAT6 inhibitor, at the AACR Annual Meeting, showcasing its anti-tumor activity in various cancer models [1][2] Group 1: OP-3136 Details - OP-3136 is a novel, orally available small molecule that selectively inhibits lysine acetyltransferase 6 (KAT6), which is an epigenetic target involved in breast and other cancers [3] - Preclinical studies indicate that OP-3136 exhibits significant anti-proliferative activity in ER+ breast cancer models and shows synergistic effects with endocrine therapies such as palazestrant and CDK4/6 inhibitors [3] - The FDA cleared the Investigational New Drug (IND) application for OP-3136 in December 2024, and the Phase 1 clinical trial is currently enrolling patients [3] Group 2: Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on improving treatment standards and outcomes for patients with breast cancer and other related conditions [4] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in a Phase 3 clinical trial [4] - Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts [4]